Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ganirelix
Drug ID BADD_D02460
Description Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is utilized frequently in assisted reproduction therapy to control the occurrence of ovulation. The drug exerts its effects by inhibiting the action of GnRH in the pituitary gland, leading to fast suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilization. Ganirelix is marketed by Merck & Co., Inc. as Orgalutran®.
Indications and Usage For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Marketing Status Not Available
ATC Code H01CC01
DrugBank ID DB06785
KEGG ID D08010
MeSH ID C061018
PubChem ID 16130957
TTD Drug ID D00RJJ
NDC Product Code 35207-0010
Synonyms ganirelix | LHRH, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)- | N-Ac-(2-naphthyl)Ala-2-(4-Cl-Phe)-3-(3-pyridinyl-Ala)-6,8-Et2-hArg-10-AlaNH2-LHRH | GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- | LHRH,N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- | ganirelix acetate | N-acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 6)-(N,N'-diethylamidino)-D-lysyl-L-leucyl-N(sup 6)-(N,N'-diethylamidino)-L-lysyl-L-prolyl-D-alaninamide diacetate (salt) | ganirelix diacetate | RS-26306-298 | RS 26306 | RS-26306 | Antagon | orgalutran
Chemical Information
Molecular Formula C80H113ClN18O13
CAS Registry Number 124904-93-4
SMILES CCNC(=NCCCCC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN=C(NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(=O)N )NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)C l)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.003921%
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.019603%
Dyspnoea22.02.01.004; 02.01.03.0020.005881%
Hepatocellular injury09.01.07.0080.003921%Not Available
Hyponatraemia14.05.04.0020.003921%
Orthopnoea02.01.03.006; 22.02.01.0200.005881%Not Available
Ovarian hyperstimulation syndrome21.11.02.007; 05.05.01.0130.115656%Not Available
Pain08.01.08.0040.003921%
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.0120.003921%
Peritoneal haemorrhage07.07.02.001; 24.07.02.0160.013722%Not Available
Pleural effusion22.05.02.0020.005881%
Premature baby18.04.02.0010.003921%Not Available
Salpingitis21.14.03.001; 11.01.10.0010.003921%Not Available
Foetal death18.01.02.003; 08.04.01.0110.003921%
Adnexal torsion21.11.02.0120.003921%Not Available
Neonatal pneumonia22.07.01.012; 18.04.12.004; 11.01.09.0170.003921%Not Available
The 1th Page    1    Total 1 Pages